Literature DB >> 22011281

The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis.

Ning Zhang1, Meena S Moran, Qiang Huo, Bruce G Haffty, Qifeng Yang.   

Abstract

Recently, several studies have published conflicting results on the alteration of biomarkers after neoadjuvant chemotherapy for breast cancer. This meta-analysis aims to evaluate the effects of neoadjuvant chemotherapy on biomarker status in breast cancer utilizing eligible studies identified through MEDLINE. This pooled analysis has demonstrated a significant change in estrogen receptor (p = .016) and progesterone receptor (p < .001) status before and after chemotherapy. Our findings suggest that in patients receiving neoadjuvant chemotherapy, hormonal receptor status is altered by the chemotherapy, and thus, consideration should be given to reevaluation of the HR status after administration of neoadjuvant chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22011281     DOI： 10.3109/07357907.2011.621913

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  25 in total

1.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Authors:  David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers
Journal:  Gynecol Oncol       Date:  2012-03-06       Impact factor: 5.482

Review 2.  Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.

Authors:  Shetal A Patel; Angela DeMichele
Journal:  Curr Oncol Rep       Date:  2017-08       Impact factor: 5.075

Review 3.  Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Authors:  O C Freedman; G G Fletcher; S Gandhi; M Mates; S F Dent; M E Trudeau; A Eisen
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

4.  Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Wei-Ping Yang; Bin Lian; Chang-Yuan Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy.

Authors:  Jia Yi Wu; Wei Guo Chen; Xiao Song Chen; Ou Huang; Jian Rong He; Li Zhu; Yafen Li; Kun Wei Shen
Journal:  Mol Clin Oncol       Date:  2014-07-31

Review 6.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

7.  The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.

Authors:  O Burgués; Mª Á López-García; B Pérez-Míes; P Santiago; B Vieites; J F García; V Peg
Journal:  Clin Transl Oncol       Date:  2017-08-09       Impact factor: 3.405

8.  Increased microRNA-221/222 and decreased estrogen receptor α in the cervical portion of the uterosacral ligaments from women with pelvic organ prolapse.

Authors:  Zhonghua Shi; Ting Zhang; Lei Zhang; Jing Zhao; Jian Gong; Chun Zhao
Journal:  Int Urogynecol J       Date:  2012-04-21       Impact factor: 2.894

9.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Authors:  Elena Provenzano; Veerle Bossuyt; Giuseppe Viale; David Cameron; Sunil Badve; Carsten Denkert; Gaëtan MacGrogan; Frédérique Penault-Llorca; Judy Boughey; Giuseppe Curigliano; J Michael Dixon; Laura Esserman; Gerd Fastner; Thorsten Kuehn; Florentia Peintinger; Gunter von Minckwitz; Julia White; Wei Yang; W Fraser Symmans
Journal:  Mod Pathol       Date:  2015-07-24       Impact factor: 7.842

10.  Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.

Authors:  Yukie Enomoto; Takashi Morimoto; Arisa Nishimukai; Tomoko Higuchi; Ayako Yanai; Yoshimasa Miyagawa; Keiko Murase; Michiko Imamura; Yuichi Takatsuka; Takashi Nomura; Masashi Takeda; Takahiro Watanabe; Seiichi Hirota; Yasuo Miyoshi
Journal:  Int J Clin Oncol       Date:  2015-09-04       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.